Sunita D Nasta Selected Research

Non-Hodgkin Lymphoma (Lymphosarcoma)

3/2023	Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy.
1/2023	Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma.
1/2022	Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting.
12/2019	Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use.
2/2017	The role of novel immunotherapies in non-Hodgkin lymphoma.
2/2014	Outcomes after involved-field radiation therapy (IFRT) with or without rituximab in patients with early-stage low-grade non-Hodgkin lymphoma (NHL) staged with CT and PET.
1/2011	NMR metabolic and physiological markers of therapeutic response.
6/2003	Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sunita D Nasta Research Topics

Disease

18	B-Cell Lymphoma (Lymphoma, B Cell) 04/2024 - 03/2004
16	Lymphoma (Lymphomas) 03/2024 - 02/2002
13	Neoplasms (Cancer) 04/2024 - 03/2004
9	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2023 - 01/2011
8	Non-Hodgkin Lymphoma (Lymphosarcoma) 03/2023 - 06/2003
5	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 03/2024 - 01/2014
5	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 12/2023 - 04/2010
5	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 01/2022 - 07/2009
4	Hodgkin Disease (Hodgkin's Disease) 11/2023 - 04/2017
3	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 12/2019 - 08/2005
2	Cytopenia 03/2024 - 08/2013
2	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2022 - 07/2012
2	Infections 01/2021 - 08/2013
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2019 - 11/2009
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2019 - 01/2018
2	Disease Progression 10/2013 - 04/2010
1	T-Cell Lymphoma (Lymphoma, T Cell) 01/2024
1	Peripheral Nervous System Diseases (PNS Diseases) 11/2023
1	Neutropenia 01/2022
1	Burkitt Lymphoma (Burkitt's Lymphoma) 03/2021
1	COVID-19 01/2021
1	Cytokine Release Syndrome 12/2018
1	Inflammation (Inflammations) 12/2018
1	Glomerulonephritis 01/2018
1	Pathologic Complete Response 12/2017
1	Bites and Stings (Sting) 02/2017
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2016
1	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2016
1	Hematologic Neoplasms (Hematological Malignancy) 07/2015
1	Philadelphia Chromosome 08/2013
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 08/2013
1	Sezary Syndrome (Sezary Erythroderma) 02/2012
1	Ischemic Optic Neuropathy (Anterior Ischemic Optic Neuropathy) 04/2007
1	Paraproteinemias (Monoclonal Gammopathy) 10/2005

Drug/Important Bio-Agent (IBA)

11	Chimeric Antigen ReceptorsIBA 03/2024 - 12/2017
7	Rituximab (Mabthera)FDA Link 12/2017 - 01/2011
5	tisagenlecleucelIBA 01/2023 - 12/2017
3	Bendamustine Hydrochloride FDA Link 04/2024 - 12/2023
3	Monoclonal AntibodiesIBA 02/2017 - 06/2003
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2023 - 01/2011
2	axicabtagene ciloleucelIBA 12/2023 - 01/2020
2	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2023 - 01/2011
2	Brentuximab VedotinIBA 11/2023 - 01/2021
2	pembrolizumabIBA 01/2022 - 02/2017
2	Methotrexate (Mexate)FDA LinkGeneric 01/2021 - 12/2017
2	Bexarotene (LGD1069)FDA Link 01/2021 - 08/2005
2	Immune Checkpoint InhibitorsIBA 01/2019 - 02/2017
2	ibrutinibIBA 01/2019 - 01/2018
2	Immunoglobulin M (IgM)IBA 12/2017 - 03/2004
2	Lenalidomide (CC 5013)FDA Link 04/2015 - 01/2014
1	brexucabtagene autoleucelIBA 03/2024
1	VaccinesIBA 03/2024
1	mRNA VaccinesIBA 03/2024
1	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 01/2024
1	fludarabineIBA 12/2023
1	Dacarbazine (DIC)FDA LinkGeneric 11/2023
1	Vinblastine (Vinblastine Sulfate)FDA Link 11/2023
1	Immune Checkpoint ProteinsIBA 03/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2021
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2021
1	venetoclaxIBA 12/2019
1	CTL019 chimeric antigen receptorIBA 12/2018
1	Immunoglobulins (Immunoglobulin)IBA 01/2018
1	Immunoglobulin A (IgA)IBA 12/2017
1	Immunoglobulin G (IgG)IBA 12/2017
1	Temozolomide (Temodar)FDA LinkGeneric 12/2017
1	AntigensIBA 02/2017
1	NivolumabIBA 02/2017
1	AntibodiesIBA 02/2017
1	blinatumomabIBA 02/2017
1	Proteins (Proteins, Gene)FDA Link 02/2017
1	nelarabine (506U78)FDA Link 01/2016
1	Anaplastic Lymphoma KinaseIBA 01/2016
1	Etoposide (VP 16)FDA LinkGeneric 01/2016
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2014
1	Histone Deacetylase InhibitorsIBA 02/2012
1	Vorinostat FDA Link 02/2012
1	Choline (Choline Chloride)IBA 01/2011
1	NucleosidesIBA 01/2011
1	Prednisone (Sone)FDA LinkGeneric 01/2011
1	Phosphates (Orthophosphate)IBA 01/2011
1	Vincristine (Oncovin)FDA LinkGeneric 01/2011
1	triphosphoric acid (triphosphate)IBA 01/2011
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2011
1	Cytotoxins (Cytolysins)IBA 11/2009
1	Sirolimus (Rapamycin)FDA Link 11/2009
1	TOR Serine-Threonine KinasesIBA 11/2009
1	denileukin diftitox (Ontak)FDA Link 04/2007
1	Blood Proteins (Serum Proteins)IBA 10/2005

Therapy/Procedure

26	Therapeutics 03/2024 - 02/2002
10	Drug Therapy (Chemotherapy) 01/2023 - 06/2003
6	Stem Cell Transplantation 01/2023 - 10/2013
4	Radiotherapy 03/2023 - 02/2014
3	Immunotherapy 01/2024 - 02/2017
3	Hematopoietic Stem Cell Transplantation 01/2022 - 07/2012
2	Transplantation 01/2023 - 12/2017
2	Organ Transplantation 10/2005 - 08/2005
2	Radioimmunotherapy 03/2004 - 06/2003
1	Off-Label Use 12/2019
1	Induction Chemotherapy 08/2013